Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-03-15
2011-03-15
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S278100, C424S283100
Reexamination Certificate
active
07906122
ABSTRACT:
The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).
REFERENCES:
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5171678 (1992-12-01), Behr et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5659011 (1997-08-01), Waldmann
patent: 5674908 (1997-10-01), Haces et al.
patent: 5783565 (1998-07-01), Lee et al.
patent: 6075012 (2000-06-01), Gebeyehu et al.
patent: 6117653 (2000-09-01), Thoma
patent: 6281371 (2001-08-01), Klosel et al.
patent: 6300321 (2001-10-01), Scherman et al.
patent: 2001/0048939 (2001-12-01), Erbacher et al.
patent: 2002/0188023 (2002-12-01), Jorgensen et al.
patent: 0 394 111 (1990-10-01), None
patent: 01-213858 (2001-08-01), None
patent: 95/21175 (1995-08-01), None
patent: 97/45442 (1997-12-01), None
patent: WO 98/05678 (1998-02-01), None
patent: WO 99/02190 (1999-01-01), None
patent: 00/37046 (2000-06-01), None
patent: 01/38295 (2001-05-01), None
patent: 01/48233 (2001-07-01), None
patent: WO 03/066068 (2003-08-01), None
patent: 2004/110496 (2004-12-01), None
patent: WO 2004/110496 (2004-12-01), None
International Search Report mailed Oct. 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000533).
International Search Report mailed Nov. 16, 2004 (corresponding PCT Appln. No. PCT/IL2004/000534).
International Search Report mailed Oct. 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000536).
Australian Patent Office Examination Report mailed Jun. 30, 2006 (corresponding Singapore Application No. SG200508078-3).
F. Brunel et al., “Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine”,Vaccinevol. 17, pp. 2192-2203, 1999.
K. Ewert et al., “Efficient Synthesis and Cell-Transfection Properties of a New Multivalent Cationic Lipid for Nonviral Gene Delivery”,J. Med. Chem. vol. 45, pp. 5023-5029, 2002.
P. L. Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure”,Proc. Natl. Acad. Sci. USA., vol.84, pp. 7413-7417, Nov. 1987.
X. Gao et al., “A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells”,Biochim. Biophys. Acta. vol. 179, pp. 280-285, 1999.
B. Guy et al., “Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine”,Vaccine, vol. 19, pp. 1794-1805, 2001.
M. A. Ilies et al., “Recent developments in cationic lipid-mediated gene delivery and gene therapy”Expert.Opin. Ther. Patents. vol. 11, No. 11, pp. 1729-1752, 2001.
K. M. Lima et al., “Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice”,Vaccine, vol. 19, pp. 3518-3525, 2001.
A. D. Miller, “Cationic Liposomes for Gene Therapy”,Chem. Int. Ed. Eng., vol. 37, pp. 1768-1785, 1987.
T. Nakanishi et al., “Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins”,J. Controlled Release, vol. 61, pp. 233-240, 1999.
M. Saminathan et al., “Ionic and Structural Specificity Effects of Natural and Synthetic Polyamines on the Aggregation and Resolubilization of Single-, Double-, and Triple-stranded DNA”,Biochemistry, vol. 38, pp. 3821-3830, 1999.
Cabral et al., “Cellular and Humoral Immunity in Guinea Pigs to Two Major Polypeptides Derived from Hepatitis B Surface Antigen” J. gen. Virol. 38, 339-350 (1978).
Diminsky et al., “Structural and Functional Characterization of Liposomal Recombinant Hepatitis B Vaccine” Journal of Liposome Research 6(2), 289-304 (1996).
Diminsky et al., “Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansen&a polymorpha): composition, structure and immunogenicity” Vaccine, vol. 15, No. 6/7, pp. 637-647 (1997).
Gavilanes et al., “Hepatitis B surface antigen - Role of lipids in maintaining the structural and antigenic properties of protein components” Biochem. J. 265, 857-864 (1990).
Gomez-Gutierrez et al., “Reconstitution of hepatitis B surface antigen proteins into phospholipid vesicles” Biochimica et Biophysica Acta 1192: 45-52 (1994).
Hermanson., “Bioconjugate Techniques” Academic Press, San Diego, CA, pp. 154-155 (1996).
Valenzuela et al., “Synthesis and assembly of hepatitis B virus surface antigen particles in yeast” Nature, 298;22 (1982).
Bareholz Yechezkel
Kedar Eliezer
Samira Sarit
Biolab Ltd.
Browdy and Neimark PLLC
Kinsey White Nicole
Lucas Zachariah
Nasvax Ltd.
LandOfFree
Sphingoid polyalkylamine conjugates for Hepatitis B virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sphingoid polyalkylamine conjugates for Hepatitis B virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sphingoid polyalkylamine conjugates for Hepatitis B virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773769